Compare Abbott Laboratories (ABT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Wheaton Precious Metals Corp — how do they compare? Abbott Laboratories trades at $111.14 (market cap $187.95B), while Wheaton Precious Metals Corp trades at $134.64 (market cap $60.94B). The key difference: Abbott Laboratories is far larger — about 3.1× Wheaton Precious Metals Corp's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | WPM | |
|---|---|---|
Market Cap | $187.95B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $165.72 |
52-Week Low | $82.57 | $91.02 |
Enterprise Value | $214.96B | $62.82B |
Dividend Yield | 2.32% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Wheaton Precious Metals (WPM) trades at $135.00, up 1.21% on the day, with a bullish technical signal supported by moving averages. The company reported record first-half 2026 results, with Q2 earnings of $1.19 per share beating estimates, driven by higher metal prices and sales volumes. Strong profitability is evident with a net income margin of 64.66% and robust cash flow from operations of $1.90 billion in 2025. Analyst consensus is strongly positive with a buy rating from 80% of covering firms and a price target of $161.75.
The outlook remains favorable given sustained high precious metal prices and operational execution, though elevated valuation multiples and potential commodity price volatility present risks. Upside is supported by consistent earnings beats and institutional confidence, but investors should weigh the stock's premium pricing against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
